David Leszkowitz, DO
Family Medicine · White Lake, MINPI 1972546299
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Alkermes, Inc. at 50.4% of the total. Reporting peaked in 2019 at $7,244 and has fallen 98.4% since, to $118 in 2024. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $99.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$11K
- MDD US Operations, LLC$5K
- AbbVie$936
- Orexo US, Inc.$646
- Indivior Inc.$544
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$356
- plus $3K from 25 others
What the payments were for
- Consulting fees$3,82518%
- Speaking & faculty fees$8,02038%
- Travel & lodging$2,84913%
- Food & beverage$6,43830%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 27 | $10,661 |
| MDD US Operations, LLC | 25 | $5,485 |
| AbbVie(2 entities) | 30 | $936 |
| Orexo US, Inc. | 22 | $646 |
| Indivior Inc. | 21 | $544 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $356 |
| Lilly USA, LLC | 18 | $317 |
| Titan Pharmaceuticals, Inc. | 3 | $305 |
| Teva Pharmaceuticals USA, Inc. | 7 | $273 |
| GSK | 5 | $244 |
| Novo Nordisk | 7 | $205 |
| Braeburn Inc. | 4 | $153 |
| Otsuka America Pharmaceutical, Inc. | 3 | $149 |
| Biodelivery Sciences International, Inc. | 2 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $117 |
| AstraZeneca | 1 | $103 |
| Ironshore Pharmaceuticals Inc. | 1 | $75 |
| Novartis | 3 | $59 |
| USWM, LLC | 3 | $50 |
| Baudax Bio Inc. | 2 | $48 |
| Gilead | 2 | $41 |
| Redhill Biopharma Inc. | 2 | $38 |
| Johnson & Johnson(2 entities) | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $35 |
| Pfizer | 1 | $22 |
| Pear Therapeutics (US), Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Orthofix Medical, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$10,118
- Lucemyra/Lofexidine$5,141
- ARISTADA$400
- Probuphine$250
- UBRELVY$241
- AJOVY$225
- BELBUCA$125
- Symproic$125
- SUBLOCADE$122
- Ozempic$120
- TRINTELLIX$117
- ABILIFY MAINTENA$114
- Mavyret$110
- VRAYLAR$106
- TEZSPIRE$103
- TRELEGY ELLIPTA$103
- BRIXADI$102
- TRULANCE$100
- ARISTADA INITIO$100
How this compares
$21,141 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 14 | $20,985 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,991 |
| Atorvastatin Calcium | 113 | $1,796 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $1,249 |
| Duloxetine Hcl | 13 | $1,133 |
| Lisinopril | 79 | $1,025 |
| Losartan Potassium | 53 | $910 |
| Levothyroxine Sodium | 70 | $773 |
| Tamsulosin Hcl | 29 | $669 |
| Metformin Hcl | 68 | $528 |
| Bupropion XlBupropion Hcl | 17 | $521 |
| Omeprazole | 36 | $484 |
| Amlodipine Besylate | 48 | $440 |
| Pantoprazole Sodium | 23 | $424 |
| ClopidogrelClopidogrel Bisulfate | 18 | $410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $317 | $20,98514 claims |
| GSKTrelegy Ellipta | $244 | $10,99112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in White Lake
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.